



## Description

5 The invention relates to a process for the preparation of recombinant polypeptides having thyrotropin-receptor activity, to nucleic acids coding for such polypeptides, and to the use of the polypeptides as obtained by the process in assay methods.

10 The literature references indicated by numbers in parentheses in this specification are listed in the form of a bibliography at the end of the description.

15 Pituitary glycoproteins (Luteinizing hormone, LH; follicle stimulating hormone, FSH; and thyroid stimulating hormone or thyrotropin, TSH) form a family of closely related hormones.

20 The pituitary hormone thyrotropin (TSH) is the main physiological agent regulating the thyroid gland. It stimulates the function and the proliferation of thyrocytes and induces the expression of differentiation (1). Most of its effects are mediated by cyclic AMP (cAMP) (1). As the other pituitary and placental glycoprotein hormones (FSH, LH, CG), TSH is a heterodimer. All these hormones share an identical alpha subunit; the beta subunit, despite sequence similarity, is specific for each (2). The activated TSH, FSH and LH-CG receptors stimulate adenylyl cyclase in their target cells via mechanisms mediated by the G protein Gs (3). In man, the TSH receptor may be the target of autoimmune reactions leading to hyper- or hypo-stimulation of the thyroid gland by autoantibodies in Grave's disease and in idiopathic myxoedema, respectively (4).

25 A prerequisite to studies of such diseases and to the elucidation of receptor structure and function is the availability of receptor preparations, particularly human, at a reasonable cost and in relative abundance.

30 To date, particulate membrane preparations and detergent-solubilised thyroid membranes, often of porcine or bovine origin (4) and (31) or (32) have been used in such studies. Human receptor preparations are not only costly but are also difficult to reproduce identically. Furthermore, the known preparations cannot be considered to be "purified" receptors; they are enriched with respect to their receptor content but do not allow purification of the receptor to a degree which would enable a partial sequence analysis, and hence its cloning.

35 Cloning and expression of the related LH-CG receptor has recently been achieved. A cDNA for the rat LH-CG receptor was isolated with use of a DNA probe generated in a polymerase chain reaction with oligonucleotide primers based on peptide sequences of purified receptor protein (15). Variants of the porcine LH-CG receptor were cloned by screening a λgt11 library with cDNA probes isolated with monoclonal antibodies (16).

40 Attempts have been made to clone the TSH receptor (6) using a method which exploits the sequence similarity displayed by all known G-protein coupled receptors. A pair of oligonucleotide primers corresponding to transmembrane segments III and VI were used on cDNA from thyroid tissue under conditions allowing amplification of the primed sequences by the polymerase chain reaction. The method did not allow cloning of the TSH receptor but led instead to the cloning of four new members of the G-protein coupled receptor family.

45 Various attempts to prepare monoclonal antibodies which recognize the TSH receptor are reported in the scientific literature as well. (33) describes monoclonal antibodies which are obtained from the fusion of human lymphocytes with myeloma cells and which are proposed as recognizing the TSH receptor because they interfere with TSH binding to human thyroid membranes and weakly stimulate cAMP production in FRTL-5 cells. However, all attempts to use said antibodies for the purification or cloning of the TSH receptor have failed.

50 (34) describes the preparation of TSH anti-idiotypic antibodies as monoclonals which are reported to recognize the TSH receptor. However, the nature of the molecules recognized by the antibodies described in (34) cannot be clearly derived from the Western blot experiments, and the authors in (34) could not identify the nature of the antigen recognized by their antibodies.

55 (35) describes the use of "antiparatypical antibodies" for detecting and treating autoimmune diseases, i.e. the use of antibodies which are raised against specific paratopes of other antibodies, i.e. against immunoglobulins. The use of antiparatypical antibodies is proposed in view of the difficulties in obtaining defined pure antigens as e.g. the TSH receptor.

(36) - a not prepublished international patent application, which claims a first priority of 8.9.1989 - reports the isolation of a cDNA clone which appears to represent a full length clone of the human TSH receptor. A deposit of said clone tr.12.6-1 was made on September 6, 1989. It was given the ATCC accession number 40651.

60 The present inventors have succeeded in cloning the TSH receptor and variants thereof, firstly by applying the technique described in (6) but with different sets of primers, and with human genomic DNA as the template, and secondly by use of a selected sequence amplified by this technique as a probe.

65 Certain aspects of the invention are illustrated in the figures 1 to 12. Figures illustrating amino-acid sequences use the one-letter abbreviation system.

70 Figure 1 is a sequence comparison of clone HGMP09 with a panel of G-protein coupled receptors ((6) and ref. therein). Only the sequence around transmembrane segment III of each receptor is shown in the one letter code. Residues conserved in HGMP09 and in more than 50 % of the other receptors are indicated by an asterisk. The "DRY" and "Asp113" residues (9) are indicated by ^.

Figure 2a shows the primary structure of the dog TSH receptor, as deduced from the nucleic acid sequence of dTSHr. The sequence was aligned (17) with full-length rat and pig LH-CG sequences (15, 16) and with HGMP09 partial sequence. Numbering is given from the first residue predicted in the mature polypeptide by von Heijne algorithm (11). Identical residues and conservative replacements in TSHr and LH-CGr are indicated by \* and ., respectively. Sites for N glycosylation are underlined. Putative transmembrane segments are overlined. Lambda phages containing dTSHr inserts were subcloned in M13 and sequenced on both strands (Applied Biosystems model 370A) using a combination of forced cloning and exonuclease III deletions (21).

Figure 2b is a dendrogram constructed from the sequences of G-protein coupled receptors. The CLUSTAL algorithm (17) was used to construct a dendrogram from the sequences of 22 receptors ((6) and references therein) including rat and pig LH-CG receptors (16, 17), HGMP09 and the TSH receptor. For each receptor, a segment corresponding to the known sequence of HGMP09 (131 residues, extending from transmembrane segments II to V) was used for comparison by the program.

Figure 3a shows TSH induced morphological changes in Y1 cells microinjected with TSH receptor mRNA. Y1 cells were microinjected with recombinant TSH receptor mRNA (0.1  $\mu$ l at 0.25  $\mu$ g/ $\mu$ l) (right) or water (left) as described (13) and incubated in control medium (upper panel) or with TSH (0.1nM) (lower panel). RO 201724 and isobutylmethylxanthine ( $10^{-6}$  M each) were present in all incubations.

Figure 3b shows TSH induced cAMP accumulation in Xenopus oocytes microinjected with TSH receptor mRNA. Xenopus oocytes were handled as described (22) and injected with water (open symbols) or recombinant TSH receptor mRNA (13) (50 nl at 0.1  $\mu$ g/ $\mu$ l) (filled symbols). After 3 days in control medium, batches of 35 oocytes were incubated for 90 min. in medium supplemented with various concentrations of TSH (circles), LH (squares) or FSH (triangles). cAMP was determined as described (14). RO 201724 and isobutylmethylxanthine ( $10^{-6}$  M each) were present in all incubations. Incubation of control oocytes in forskolin at  $10^{-4}$  M resulted in doubling of the cAMP concentration (not shown).

Figure 4 illustrates the displacement of  $^{125}$ I TSH receptors expressed in cos7 cells. Cos7 cells were transfected with TSH receptor cDNA subcloned in pSVL (23). After 72 hours, cells were harvested and a membrane fraction was prepared (24). Membranes were similarly prepared from wild type cos7 cells and from dog thyrocytes in primary culture (20). Binding of  $^{125}$ I TSH (TRAK Henning) was performed at 0°C for 120 min. in the presence of various concentrations of competitors (TSH-Armour, FSH and LH, UCB bioproducts). Bound radioactivity was separated by centrifugation and counted. Results are expressed as percent  $^{125}$ I TSH bound by transfected cells in the absence of competitor (3,000 cpm) over nonspecific binding (radioactivity bound in the presence of 100nM cold TSH, 800 cpm). Open and filled circles represent displacement by cold TSH from cos7 and thyrocyte membranes respectively. Open and filled squares represent displacement from cos7 by LH and FSH, respectively. Diamonds represent control cos7 cells in presence of various amounts of cold TSH.

Figure 5 shows the cDNA sequence coding for the dog TSH receptor, which was expressed in oocytes and culture cells.

Figure 6 is schematic representation of the dog thyrotropin receptor, showing the 7 putative transmembrane segments and the large NH<sub>2</sub> terminal extracellular domain (to the exclusion of the signal peptide). The amino-acids deleted in the variant form are indicated in black. The five putative glycosylation sites are shown.

Figure 7 shows the sequence alignment of the repeats constituting the extracellular domain of the thyrotropin receptor amino-acid sequence. The signal peptide, as determined by Von Heijne algorithm is represented in italic. The repeat missing in the molecular variant of the receptor is indicated by the leftward arrow.

Figure 8 shows the primary structure of the human TSH receptor as deduced from its cDNA sequence. The amino-acid sequence corresponds to the 2292 nucleotide open reading frame determined from the sequencing of two overlapping inserts in lambda gt11 clones (see examples). It is aligned for comparison with the dog TSH receptor sequence (only non conserved amino-acids are indicated). Numbering starts from the first residue of the mature polypeptide as determined by von Heijne algorithm [11]. Potential N-glycosylation sites are underlined and putative transmembrane segments are overlined.

Figure 9 shows the displacement by nonradioactive TSH of [ $^{125}$ I]TSH from human TSH receptors expressed in cos-7 cells. Results are expressed as percentage of the [ $^{125}$ I]-labelled TSH bound by transfected cells in the absence of competitor (1400 cpm) after correcting for nonspecific binding (radioactivity bound in the presence of 100 nM unlabelled TSH, 240 cpm).

Figure 10 represents the displacement by immunoglobulins of [ $^{125}$ I]TSH from human TSH receptor expressed in cos-7 cells. Results are expressed as described in the legend to fig. 9. Immunoglobulins were prepared (see examples) from a normal individual (N), from patients with idiopathic myxoedema (IM1, IM2) or Graves' disease (GD1, GD2). The concentration of immunoglobulins in the assay is indicated. The ability of IM1 and IM2 (1.5 mg/ml) to inhibit TSH-stimulated cAMP production in a human thyrocyte assay was 100 % and 85 %, respectively. The thyroid stimulating activity of GD1 and GD2 (1.5 mg/ml) was equivalent to that of 10 mU/ml of TSH, respectively.

Figure 11 shows the primary structure of a TSH receptor according to the invention, in which a plurality of letters

at any one site indicates the presence of one of the given amino acid residues at that site.

Figure 12 illustrates the cDNA sequence of the cloned human TSH receptor.

The invention relates to a process for the preparation of a recombinant polypeptide possessing thyrotropin receptor activity, which polypeptide comprises an amino-acid sequence represented by the following general formula:

5

$$[X]_n - [Y]_m - [Z]_p$$

wherein n = 0 or 1; m = 1; p = 0 or 1;

10 and X, Y and Z are defined as explained below;

the process comprising the expression of a nucleic acid coding for the polypeptide in a host cell transformed by a vector in which the said nucleic acid has been operationally inserted, and which polypeptide, in the case of p = 1, further is characterized in that it is associated with such a host cell, the receptor thus being present in a non-thyroidal cellular environment, or with a membrane preparation which is free of impurities associated with detergent-solubilized thyroid membrane preparations.

15 The invention further relates to nucleotides to be used in the process of the invention and to certain preferred uses of the polypeptide preparations obtained by the process of the invention.

20 By "TSH-receptor activity" is meant either TSH-binding properties or anti-TSH receptor antibody-binding properties or the ability to activate adenylyl cyclase or phospholipase C via G proteins when exposed to TSH or anti-TSH receptor antibodies. These properties are easily verified by contacting the polypeptide with for example labelled TSH or labelled anti-TSH receptor antibodies or by monitoring the adenylyl cyclase activity of a membrane preparation containing the polypeptide. The polypeptides of the invention include the entire TSH receptor as identified by the inventors, and fragments or variants of this polypeptide as defined below. The entire TSH receptor is composed of a signal peptide (20 residues) followed by a large putative extracellular domain (398 residues) containing 5 sites for N-glycosylation, connected to a 25 346 residue COOH domain containing seven putative transmembrane segments. The amino-acid sequence of the complete receptor is illustrated in fig. 11.

25 More particularly, the invention relates to a process for the preparation of a recombinant polypeptide possessing thyrotropin receptor activity, which polypeptide i) is characterised in that it comprises an amino-acid sequence represented by the following general formula:

30

$$[X]_n - [Y]_m - [Z]_p$$

wherein n = 0 or 1; m = 1; p = 0 or 1;

35 and X, Y and Z are defined as follows (using the one-letter amino-acid symbol and wherein a plurality of letters at any one site indicates the presence of any one of the given amino-acid residues at that site):

40

$$X = \begin{matrix} M R P A D L L Q L V L L L D L P R D L \\ P P \quad H \quad A \quad A \quad S \end{matrix}$$

45 Y = at least the minimum number of consecutive amino-acids of the following sequence necessary for the presentation of immunogenic properties:

45

50

55

GGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLI  
 K P D H T F

5 ETLRLTIPSHAFSNLPNISRIYVSIDLTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPD  
 Q K R L A R M S S

ALKELPLLKFLGIFNTGLKMFPLDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETL  
 GV V V A A

10 TLKLYNNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTA  
 I H SA T Y

15 LPSKGLEHLKELIARNTWLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLM

CNESSMOSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQE  
 IR T G FD Y HA DN Q DS S

20 DEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCED  
 L V GN

and Z = [I - II - II<sub>i</sub> - III - III<sub>i</sub> - IV - V - VI - VII - VII<sub>i</sub>] wherein the amino-acid sequences I - II - II<sub>i</sub> - III - III<sub>i</sub> - IV - V - VI - VII - VII<sub>i</sub> are independently present or absent and have the following meanings:

25 I = IMGYKFLRIVVWFVSSLALLGNVFVLLILLTSHYK  
 IV

30 or at least 12 consecutive amino-acid residues of this sequence;

35 II = LNVPRFLMCNLAFADFCMGMYLLIASVDLYTHSEYYNHA  
 T I I IH K Q H Y

40 or at least 12 consecutive amino-acid residues of this sequence;

45 II<sub>i</sub> = IDWQTGPGC  
 A

or at least 2 consecutive amino-acid residues of this sequence;

50 III = NTAGFFTVAFAESELVYTLTVITL  
 DA

or at least 22 consecutive amino-acid residues of this sequence

55 III<sub>i</sub> = ERWYAITFAMRLD  
 HT H Q

or at least 2 consecutive amino-acid residues of this sequence;

5           IV = RKIRLRHACAIMVGGWVCCFLLALLPLVGISSYAKVSICL  
               C VQ       Y SV       M IFA AA   F IF       M  
               A

or at least 12 consecutive amino-acid residues of this sequence;

10           V = PMDTETPLALAYIVFVLTLNIVAFVIVCCCYVKIYITVRN  
               IDS   SQL VIL   L   VL   I   S  
               MSL V

15           or at least 12 consecutive amino-acid residues of this sequence;

20           VI = PQYNPGDKDTKIAKRMALIFTDFICMAPISFYALSAILNKPLIT  
               M   LM

25           or at least 12 consecutive amino-acid residues of this sequence;

30           VII = VSNSKILLVLFYPLNSCANPFLYAIIFTKAFQRD  
               T

35           or at least 12 consecutive amino-acid residues of this sequence;

40           VII<sub>1</sub> =

45           VFILLSKFGICKRQAQAYRGQRVPPKNSTDIQVQKVTHDMRQGLHNMEDVYELIENS  
               S       AG   I       R       S P   Q E   L

50           HLTPKKQQQISEEYMQTVL  
               N       K    N

55           or at least 12 consecutive amino-acid residues of this sequence;

it being understood that any of the above-specified amino-acids can be replaced or deleted, and that extra amino-acid residues may be inserted provided the thyrotropin receptor activity is maintained, and which polypeptide, ii) in the case of p = 1, further is characterized in that it is associated with a membrane preparation which is free of impurities associated with detergent-solubilized thyroid membrane preparations, by the expression of a nucleic acid coding for the polypeptide in a host cell transformed by a vector in which the said nucleic acid has been operationally inserted.

The sequence represented by [x]<sub>n</sub> in the above general formula corresponds to the signal sequence of the TSH receptor. This part of the polypeptide naturally ensures the transport to the cell membrane of the adjoining [y] and/or [z] fragments, after its production in the cell. Clearly the signal sequence does not need to be present in the polypeptide in cases where transport to the membrane is not required (for example in in vitro translation of the mRNA encoding the polypeptide), or may be replaced by other signal sequences to facilitate production of the recombinant receptor in certain host cells.

The sequence represented by [z]<sub>p</sub> in the above general formula corresponds to the COOH domain of the entire polypeptide containing the seven putative transmembrane fragments I-VII, which show homology with the correspond-

ing region of other G-protein coupled receptors. The polypeptides of the invention include, as indicated above, variants of the basic TSH receptor sequence lacking part or all of the transmembrane domain. It is thought that these types of variants may exist naturally as a result of an alternative splicing phenomenon. By homology with other, known G-protein coupled receptors, the seven putative transmembrane segments have tentatively been identified as shown in Fig. 11 (numbered I to VII). The variant polypeptides of the invention include polypeptides missing some or all of the fragments I - VII; as defined above, which definition includes the putative extracellular and intracellular "loops" occurring between the transmembrane segments (see fig. 6). The transmembrane segment(s) missing may therefore, for example, be a segment selected from segments I to VII as indicated in fig. 11 or may be part of one of those segments, or may be a transmembrane segment in conjunction with its adjoining intracellular and/or extracellular loop.

It is also within the terms of the invention to replace some or all of the transmembrane domain by the transmembrane domain, or part of this domain, of a different receptor, thus giving rise to a hybrid receptor. This type of receptor could be particularly interesting in cases where the extracellular part of the TSH receptor needs to be anchored in a cell membrane having characteristics which are different from, or even incompatible with, the transmembrane portion of the TSH receptor. It is also possible to use as the transmembrane domain in a hybrid receptor any amino-acid sequence exhibiting suitable anchoring properties. Such a sequence could be entirely synthetic or based on any transmembrane protein.

It is to be noted that the invention also embraces the preparation of polypeptides having thyrotropin receptor activity which lack the entire transmembrane domain. In this case, the polypeptide corresponds to the extracellular domain of the naturally occurring receptor. This extracellular part of the receptor which is apparently responsible for ligand binding, is identified by the region [y] in the general formula. A polypeptide lacking the entire transmembrane domain is represented by the general formula [y]<sub>m</sub>, where m = 1, the [z] part of the sequence being absent. This extracellular part of the receptor [y], is characterised by an imperfect repeat structure which can be aligned as shown in Fig 7. The polypeptides of the invention include variants in which one or more of these repeats is missing. It is however important that sufficient aminoacids be present to allow formation of antibodies (monoclonal or polyclonal). Such immunogenic amino-acid sequences may comprise for example 5, 6, 7, 8 or 9 consecutive amino-acids of the "y" sequence defined above.

In particular, the invention encompasses the preparation of polypeptides in which the second repeat (marked by an arrow in fig 7) is missing.

The invention also relates to nucleic acid sequences coding for the polypeptides of the invention as well as the corresponding complementary sequences. Examples of such sequences are those shown in figs. 5 and 12, and fragments of these sequences, as well as corresponding degenerate sequences. The nucleic acid fragments embraced by the invention normally have at least 8 nucleotides and have preferably at least 12 or preferably at least 16 nucleotides. Such fragments, or their complementary sequences can be used as primers in the amplification of segments of DNA using the polymerase chain reaction, for example in the production of cDNA coding for the polypeptides having thyrotropin receptor activity.

The process of the invention can be conducted in several different ways. For example, a host cell such as COS 7 cells, CHO cells, NIH3T3 cells, Xenopus oocytes or Y1 cells can be transformed by a vector containing a nucleic acid insert coding for the desired peptide, in conjunction with all the necessary regulatory elements such as promoter, transcription termination signals etc, or microinjected with recombinant mRNA transcribed from appropriate vectors containing the receptor encoded sequence. Expression of the insert normally leads to the insertion of the recombinant polypeptide in the membrane of the cell used as host. In this way, the receptor polypeptide can be used in this form, the receptor thus being present in a cellular environment, or in a solubilised membrane fragment form.

Furthermore, in the case where only a fragment of the polypeptide is required, the correspondingly shorter nucleic acid sequence can be used to transform a suitable host cell, for example, a DNA coding for the putative extracellular region only, or one or more repeats of the repetitive portion of this region.

The invention also makes available antibodies, both polyclonal and monoclonal, to the thyrotropin-receptor polypeptides. As mentioned earlier, in man the TSH-receptor may be the target of autoimmune reactions giving rise to hyper- or hypo-stimulation of the thyroid gland by stimulating and blocking autoantibodies respectively. The antigenic nature of the polypeptides of the invention, particularly the putative extracellular domain, permits the preparation of antibodies, which can be used in a variety of studies and assays. The TSH-receptor binds both TSH and anti-TSHr antibodies, thus it is possible in certain studies to replace TSH by anti-TSHr antibodies. The phenomenon of competition between labelled and unlabelled species is particularly useful in such assays.

One such assay falling within the terms of the invention is a process for the quantitative detection of thyrotropin (TSH) or of anti-thyrotropin receptor antibodies (anti-TSHr) in a biological sample wherein a polypeptide obtained according to the process of the invention is contacted with the biological sample suspected of containing TSH or anti-TSHr antibodies and, either simultaneously or subsequently, contacted with labelled TSH, or with labelled anti-TSHr antibodies and the remaining, bound labelled TSH or bound labelled anti-TSHr antibodies after competition between the labelled and unlabelled species, is measured.

In this type of assay, the competition between the labelled TSH or labelled antibodies with the unlabelled TSH or antibodies present in the biological sample is measured as an indication of the concentration of that species in the sample.

Alternatively, instead of using competition between two like-species to measure TSH, it is also possible to use a receptor polypeptide to bind the TSH in the biological sample, and then after washing to add labelled anti-TSH antibodies which selectively detect the bound TSH. This type of assay can also be carried out using immobilized or solubilized receptor polypeptide to bind the anti-TSHr-antibody in a biological sample, followed by detection of the bound antibody by labelled anti-immunoglobulins or protein A or protein G or any other agent capable of recognizing an antibody.

Another means of assaying the TSH or anti-TSHr antibodies in a sample exploits the effect which the binding of these species with the TSH receptor has on the adenylyl cyclase activity of the cell bearing the receptor. Thus, this aspect of the invention relates to a process for the quantitative detection of TSH or of anti-TSHr antibodies by contacting intact cells operationally transformed by a nucleotide sequence, encoding a polypeptide of the invention or membrane preparations of such cells with the biological sample suspected of containing TSH or anti-TSHr antibodies and measuring in the intact cells or membranes the change in adenylyl cyclase activity, for example by measuring C-AMP generation or release.

The binding of TSH itself or of stimulating anti-TSHr antibodies to the receptor polypeptide leads to an increase in adenylyl cyclase activity, whereas the binding of blocking anti-TSHr antibodies leads to an inhibition of TSH-induced adenylyl cyclase stimulation. By comparing the adenylyl cyclase activity induced by exposure of the receptor polypeptide to TSH with that induced by antibodies in a sample, it is possible, according to the invention, to distinguish blocking antibodies from stimulating antibodies. In order to quantitatively determine blocking antibodies in a sample, the sample is contacted with the receptor polypeptides either at the same time as with TSH, or before contacting with TSH. In this way the adenylyl cyclase stimulating effect of TSH on the receptor is blocked by the blocking antibodies and is quantified to indicate the concentration of blocking antibodies present in the sample. Such measurements can be carried out in intact cells bearing the TSH receptors of the invention, or in membrane preparations of such cells. Other effector systems which can be used in this type of detection are, for example, activities of phospholipase C, protein tyrosine kinase, phospholipase A2 etc.

The labels used in the different assays mentioned are those conventionally used in the art, for example, radioactive labelling, enzymatic labelling, labelled anti-immunoglobulins, protein A, protein G, depending upon the type of assay.

Another aspect of the invention relates to a process for the quantitative detection of fragments of TSH receptor in a biological fluid. Such fragments may be found circulating in patients suffering from thyroid disorders. This aspect of the invention involves contacting the sample with antibodies raised against the recombinant polypeptides which have previously been labelled, if necessary, and determining the binding, if any, in the sample by any method involving separation of bound labelled antibody from unbonded labelled antibody or by competition between the said fragments and a polypeptide according to the invention. In this latter case it is necessary to label the receptor polypeptide, for example with  $^{125}\text{I}$ .

Said antibodies may also be used in the immunohistochemical detection of TSH receptors, for example in endocrinological investigations or in anatomopathology. In this type of process, the antibodies are again labelled to permit their detection.

The polypeptides prepared by the process of the invention may also be used in the purification of stimulating or blocking antibodies to TSHr and of TSH by contacting the polypeptide with a source of TSH or anti-TSHr antibodies, separating the bound and free fractions and finally dissociating the receptor-bound entity. If necessary, further successive purification steps known *per se* may be added. Such a purification process is facilitated by the immobilisation of the receptor polypeptide, for example in a column or any other solid support.

On the basis of the present invention, there can be designed kits suitable for the detection of TSH or anti-TSHr antibodies. Such kits are characterised in that they contain:

- a) a polypeptide as defined above, said polypeptide having thyrotropin receptor activity and being either in an immobilised or solubilised form;
- b) at least one of the following reagents:
  - i) labelled TSH
  - ii) labelled anti-TSHr antibodies
  - iii) reagents necessary for the measurement of adenylyl cyclase activity.

For example, a kit for effecting the detection of autoantibodies directed against the TSH receptor by competition would include the polypeptide prepared by the process of the invention, in immobilised or solubilised form, with labelled TSH or unlabelled TSH in combination with agents permitting the TSH to be labelled. Alternatively, such a kit might

include antibodies to the TSH receptor and means of labelling them, instead of the TSH.

The invention will be illustrated by the following examples:

Examples

5

I - Cloning of dog TSHr

10


a) Identification of HGMP09

15

As most G protein-coupled receptor genes do not contain introns in their coding sequence, a similar strategy to that previously described (6) was used, but using different sets of degenerated primers and with human genomic DNA as starting material. Eleven clones displaying sequence similarity with G-protein coupled receptors were thus obtained (7). Out of these, one clone (HGMP09) which was amplified with primers corresponding to transmembrane segments II and VII, presented sequence characteristics suggesting that it belonged to a distinct subfamily of receptors.

15

The primers used in this amplification were:



a plurality nucleotides  
 at any one site indicating  
 the presence of one of  
 the given nucleotides at  
 that site

25

A dendrogram constructed from the alignment shown in fig. 1 demonstrated that it is equally distant from all receptors cloned to date (7); in particular, it does not contain the canonical Asp Arg Tyr (DRY) tripeptide close to transmembrane segment III (8) and lacks the Asp residue implicated in the binding of charged amines is adrenergic (Asp113), muscarinic, dopaminergic and serotonergic receptors (9).

30

b) Identification of dog TSHr

35

In the frame of a systematic screening for the expression of the new receptors in thyroid tissue, HGMP09 was used as a probe both in Northern blotting experiments with thyroid and non-thyroid tissues, and in screening of a dog thyroid cDNA library. HGMP09 did not hybridize to thyroid mRNA but identified a major 2.6 kb transcript in the ovary and the testis. However, under moderate conditions of stringency it hybridized to one out of 50,000 thyroid cDNA clones suggesting cross-hybridization with a relatively abundant putative receptor of the thyroid. From these characteristics, it was hypothesized that HGMP09 encoded a receptor fragment, distinct from the TSH receptor, but with sequence characteristics expected from close relatives like LH or FSH receptors. A full-length cross-hybridizing clone (dTSHr) was isolated and used as a probe in Northern blots of ten different dog tissues. It hybridized to a 4.9 kb transcript present only in the thyroid gland and in cultured thyrocytes. Interestingly, the signal was much stronger in cultured thyrocytes exposed for several days to the cAMP agonist forskolin than in thyroid tissue. This is a characteristic one would expect from the TSH receptor whose expression is known to be up-regulated by cAMP agonists in cultured cells (10). A 4,417 bp cDNA clone was sequenced completely. It contains an open reading frame of 764 aminoacids beginning with a 20 residue signal peptide, as predicted by Von Heijne algorithm (11) (fig.2a). Comparison to known G-protein coupled receptors (see hereunder and fig. 2b) and hydropathy profile analysis (not shown) demonstrated a 346 residue C-terminal structure with seven putative transmembrane domains preceded by 398 aminoacids constituting a large putative extracellular domain.

50

c) Expression of dog TSHr

55

The encoded polypeptide was unambiguously identified as the TSH receptor by expression of the cDNA in a variety of systems. Microinjection of recombinant mRNA in adrenocortical Y1 cells and in *Xenopus* oocytes conferred a TSH responsive phenotype to both systems. Y1 cells responded to TSH by a characteristic morphological change which is triggered by elevation of cAMP in the cytoplasm (12,13). *Xenopus* oocytes (fig. 3) displayed a dose-dependant increase in cAMP which was specific for stimulation by TSH and corresponded to the expected sensitivity of the dog receptor to bovine TSH (half-maximal effect around 0.3 nM) (14). Transient expression of the receptor cDNA was obtained in Cos7 cells (fig 4). Specific binding of <sup>125</sup>I TSH to membranes was observed only in transfected cells. The displacement curve

of the label by TSH presented characteristics very similar to that obtained with membranes from dog thyrocytes (half-maximal displacement at 0.4 nM and 0.16 nM for cos cells and thyrocytes, respectively) (fig. 4c). The slight rightward shift of the displacement curve obtained with Cos7 cell membranes may reflect the higher amount of receptors in this system.

5 The cDNA coding for the dog TSH receptor was sequenced completely. The sequence is given in fig. 5.

d) Comparison of TSHr with LH-CGr

10 Comparison of the TSH receptor with the LH-CG receptor cloned recently (15, 16) reveals interesting common characteristics which make them members of a new subfamily of G-protein coupled receptors. They both display a long aminoterminal extension containing multiple sites for N glycosylation (five in the TSH receptor). The TSH receptor has an extra 52 residue insert close to the junction between the putative extracellular domain and the first transmembrane segment (fig. 2a). The overall sequence similarity between the extracellular domains of the TSH and LH-CG receptors is 45% (fig 2a). The similarity between a segment of soybean lectin and the rat LH receptor (15) is not conserved in the TSH receptor, which suggests that it may be fortuitous. The C-terminal half of the TSH receptor containing the transmembrane segments is 70% similar to both the pig and rat LH receptors (fig. 2a). The homology is particularly impressive in the transmembrane segments themselves, where stretches of up to 24 identical residues are observed in a row (transmembrane region III). Also, the carboxyl terminal region of the third putative intracellular loop, which is particularly short in TSH and LH receptors and which has been implicated in the interaction with  $G_{\alpha s}$  (8, 9), is identical in both receptor types. This pattern of similarities gives support to the view that the extracellular domain would be involved in the recognition of the ligands (4), while the membrane-inserted domain would be responsible for the activation of  $G_{\alpha s}$  (15, 16). Together, the TSH and LH-CG receptors, and HGMP09 (there is strong preliminary evidence that HGMP09 could actually be the FSH receptor (7)) constitute clearly a distinct subfamily of G-protein coupled receptors. A sequence similarity dendrogram (17) including most of the G-protein coupled receptors cloned to date demonstrates both their close relationships and their distance from the bulk of the other receptors (fig. 2b). The complete sequence of the FSH receptor will reveal whether the known ability of LH-CG to stimulate the TSH receptor (18) is reflected by a higher sequence similarity of the extracellular domains of LH and TSH receptors.

30 e) Identification of a dog TSHr variant

35 Screening of the dog thyroid cDNA library (30) with the HGMP09 clone (thought to be part of the FSH receptor), gave rise to 16 positive clones out of the 840,000 screened plaques. Hybridization was carried out at 42°C in 35% formamide and the filters were washed at 65°C in 2 x SSC, 0.1% SDS before autoradiography. 12 clones were purified to homogeneity and analyzed by EcoRI digestion. Three clones (dTSHR1, dTSHR2 and dTSHR3) were subcloned in M13mp18 and pBS vectors. dTSHR1 and dTSHR2 consisted of two EcoRI fragments of respectively 2800 and 1500 bp. dTSHR3 was shorter, and consisted of 2200 and 1500 bp EcoRI fragments. Restriction analysis of the 2800 bp fragments of dTSHR1 and dTSHR2 revealed slight differences in the restriction map, the main discordance being the presence of a PstI restriction site in dTSHR1 and its absence in dTSHR2. dTSHR1 was sequenced completely and revealed an open reading frame of 764 codons which was identified as the thyrotropin receptor by expression of the cDNA in oocytes and cell cultures (see example I(b) + fig 5). dTSHR3 was shown by sequencing to be completely colinear with dTSHR1 but this clone lacked 600 bp at its 5' end. Because of the difference in the restriction map of dTSHR1 and dTSHR2, this latter clone was also sequenced on both strands.

40 The sequence revealed a number of mutations when compared with the dTSHR1 clone. A total of 5 mutations, including two single base substitutions, one single base deletion, one single base insertion and one 5 base insertion were found scattered in the 2060 bp long 3' untranslated region (not shown). However, the main difference between dTSHR2 and dTSHR1 was located in the coding region, and consisted in a 75 bp deletion located 240 bp after the start codon. The corresponding 25 amino-acids deletion in the protein itself is located in the long NH2 terminal extracellular domain which is characteristic of the TSH receptor (25) and its recently cloned close relative, the LH receptor (15, 16) (fig. 6). As in the LH receptor, the NH2 terminal part of the thyrotropin receptor is characterized by an imperfect repeat structure that can be aligned as indicated in fig. 7. These repeats are similar in structure to the leucine-rich repeats found in the various proteins comprising the family of leucine-rich glycoproteins (26, 15, and references therein). The deletion in the dTSHR2 clone corresponds exactly to one of these repeats, in a region of the protein where the repeat length is regular and their alignment unambiguous. The existence of such variant reinforces considerably the significance of this repeated structure and sets up interesting questions concerning its functional meaning and the structure of the chromosomal gene.

45 The extracellular domains of TSH and LH receptors are apparently responsible for the ligand binding (4). The deleted repeat also contains one of the 5 consensus sequences for N-glycosylation. Glycosylation of the TSH receptor could be important for ligand binding or signal transduction. If, and to what extent, the lack of this repeat influences

the binding capabilities and/or the function of the receptor variant, is not yet known. Comparison of cell lines expressing this variant with the presently available stable transfectants expressing the full size receptor should partially answer this question. The functional analysis of other in-vitro generated mutants of the TSH receptor will complete the study.

The deletion of a full repeat gives also some insight on the structure of the TSH receptor gene. It is highly probable that the repeat unit corresponds to a complete exon, and it is therefore possible that all repeats would be separated by introns. It is interesting to note that most of the genes coding for G-protein coupled receptors are completely devoid of intronic structures. The functional or evolutionary significance of this observation is not known, but a highly fragmented exonic structure of the glycoprotein hormone receptor genes would be in clear contrast to the rest of the receptor family.

10

## II - Cloning of the human TSHr

A human lambda gt11 cDNA library (29) was screened with a fragment of the dog TSHr (25). Out of the 218 clones scored as positive (1/16000), 24 were plaque-purified to homogeneity and the size of the inserts was determined. Two clones which harbored inserts of 2370 bp and 3050 bp, respectively, were subcloned as overlapping fragments in M13 derivatives and sequenced (fig 12). A total of 4272 bp were determined in which a 2292 bp open reading frame was identified. When translated into protein, the coding sequence showed an overall 90.3 % similarity with the dog TSHr (Fig. 8) [1]. It displayed all the characteristics described recently for the subfamily of G protein-coupled receptors binding glycoprotein hormones (25, 15, 16); a signal peptide (20 residues) followed by a large putative extracellular domain (398 residues) containing 5 sites for N-glycosylation, connected to a 346 residue carboxyl-terminal domain containing seven putative transmembrane segments (fig. 8). It has been suggested that the amino-terminal domain, which is not found in other G protein-coupled receptors, might correspond to the region involved in the binding of the bulky pituitary and placental glycoprotein hormones (25, 15, 16).

25

### Variants of the hTSHr

When probed with the putative human TSHr, a Northern blot of RNA from human placenta, testis and thyroid revealed two major 4.6 and 4.4 kb thyroid-specific transcripts. Minor thyroid-specific RNA species of smaller size were also observed. Although the former could simply correspond to multiple polyadenylation sites in the 3' region of the gene, this situation is reminiscent of what has been observed for the porcine LH-CG receptor. In this case, multiple transcripts were found to correspond to variants of the receptor cDNA lacking the potential to encode the membrane spanning segments (16). Whether this observation with important implications on receptor function and regulation also applies to the human TSHr will await sequencing of additional clones from the cDNA library.

35

### Expression of hTSHr

To provide definite proof that the clones isolated encoded a human TSH receptor, the coding sequence was inserted in the SV40-based vector pSVL, and the resulting construct transfected in Cos-7 cells (24). Membranes prepared from transfected cells demonstrated specific binding of [<sup>125</sup>I]TSH (fig. 9). The unlabelled competitor TSH was bovine. The characteristics of the displacement curve with unlabelled TSH were similar to those observed with the dog TSHr assayed under similar conditions (half maximal displacement around 0.5 nM) (25).

From the sequence similarity with dog TSHr, the tissue specific expression of the corresponding transcripts and the binding studies on membranes from transfected COS-7 cells, it was concluded that a **bona fide** human TSHr has been cloned.

45

### Antibodies to hTSHr

To investigate the relevance of the cloned human TSHr to thyroid autoimmunity, competition was tested between [<sup>125</sup>I]TSH and immunoglobulins prepared from patients, for binding to the recombinant receptor expressed in Cos-7 cells (fig 10). Immunoglobulins were prepared from the serum of patients or normal individuals by ammonium sulphate precipitation. They were dissolved in water and dialysed extensively against Dulbecco's modified Eagle medium. While immunoglobulins from normal individuals did not displace [<sup>125</sup>I]TSH, samples from two patients with idiopathic myxoedema clearly did, in a dose-dependant manner. The steep dose-response which was observed suggests that immunoglobulins from these patients present a very high affinity for the recombinant receptor. When samples from two patients with Graves' disease having high levels of thyroid stimulating immunoglobulins in the circulation were tested, one of them showed limited ability to displace labelled TSH under the conditions of the assay (fig.10). The difference in the potency of these two categories of immunoglobulins to displace TSH from the receptor expressed in Cos-7 cells may reflect differences in their affinity for a common antigen. Alternatively, despite previous studies suggesting that

both stimulating and blocking antibodies would bind to the same part of the TSHr (26, 27), it may correspond to more basic differences in the actual nature of their respective antigenic targets. Studies where binding activity of a larger collection of immunoglobulins are compared to their ability to activate adenylate cyclase in permanently transfected cells will help to clarify this point.

5

#### Bibliography

1. J.E. Dumont, G. Vassart & S. Refetoff, in *The Metabolic Bases of Inherited Diseases*, C.R. Scriver, A.L. Beaudet, W.S. Sly & D. Vale eds. McGraw-Hill, pp 1843-1880 (1989).
- 10 2. I.A. Kourides, J.A. Gurr & O. Wolw, *Rec. Progr. Horm. Res.* 40, 79-120 (1984)
3. F. Ribeiro-Neto, L. Birnbaumer and J.M.B. Field, *Mol. Endo.* 1, pp 482-490 (1987).
- 15 4. B. Rees-Smith, S.M. McLachlan & J. Furmaniak, *Endocrine Rev.* 9, 106-121 (1988).
5. R.K. Saiki et al., *Science* 239, pp. 487-491 (1988).
- 20 6. F. Libert et al., *Science* 244, pp. 569-572 (1988).
7. M. Parmentier et al; to be published elsewhere.
8. B.F. O'Dowd, et al. *J. Biol. Chem.* 263, 15985-15992 (1988).
- 25 9. C. Strader, I.S. Sigal & R. Dixon. *FASEB J* 3, 1825-1832 (1989)
10. S. Lissitzky, G. Fayet and B. Verrier. *Adv. Cyclic Nucl. Res.* 5, 133-152 (1975).
- 30 11. G. von Heijne, *Nucl. Acids Res.* 14, 4683 (1986).
12. B.P. Schimmer, in *Functionally Differentiated cell lines*. pp 61-92. G. Sato, ed. AlanR. Riss Inc. (1981) N.Y.
- 35 13. C. Maenhaut & F. Libert, submitted. Y1 cells were grown as monolayers as described (12). 1 mm<sup>2</sup> areas were marked on the bottom of the dishes and all cells in these areas were microinjected with mRNA at 0.25 ug/ul in water. mRNA was synthesized from TSH receptor cDNA subcloned in pSP64 (Promega). After 30 min., TSH was added and the cells were photographed 120 min. later. The morphological changes (stable for 20 hours) were observed with TSH concentrations down to 0.1 nM. FSH, LH and hCG were ineffective (not shown).
- 40 14. J. Van Sande, P. Cochaux and J.E. Dumont. *FEBS Lett.* 150, 137-141 (1982).
15. K.C. Mcfarland et al., *science* 245, 494 (1989).
16. H Loosfelt et al., *ibid* 245, 525, (1989).
- 45 17. D.G. Higgins and P.M. Sharp, *Gene*, 73, 237-244 (1988).
- 18 J.G. Kenimer, J.M. Hershman & H.P. Higgins. *J. Clin. Endopd. Metab.* 40, 482 (1975).
- 50 19. T. Maniatis, E.F. Fritsch and J. Sambrook, (1982) In *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, New York).
20. P. Roger et al. *Eur. J. Biochem.* 152, 239-245 (1985).
- 55 21. F. Sanger, S. Nicklen & A.R. Coulson. *Proc Natl. Acad. Sci. U.S.A.* 74, 5463 (1977). S. Henikoff. *Gene* 28, 351 (1984).
22. B.K. Kobilka et al. *J. Biol. Chem.* 262, 7321 (1987).

23. G. Wong, Y.S. et al. *Science* 228, 810-815 (1985).

24. R.A.F. Dixon et al. *Nature* 326, 73-77 (1987).

5 25. Parmentier, M., Libert, F., Maenhaut, C., Lefort, A., I Gérard, C., Perret, J., Van Sande, J., Dumont J.E. and Vassart, G. (1989). Submitted.

26. Takahashi, N., Takahashi, Y. and Putman, F.W. (1985). *Proc. Natl. Acad. Sci. U.S.A.* 82, 1906.

10 27. Davies Jones, E., Hashim, F., Creagh, F. Williams, S. and Rees Smith, B. (1985) *Mol. Cell. Endo.* 41, 257-265.

28. Amino, N., Watanabe, Y., Tamaki, H., Iwatani, Y; and Miyai, K. (1987) *Clin. Endo.* 27, 615-620.

15 29. Libert, F., Ruel, J., Ludgate, M., Swillens, S., Alexander, N., Vassart, G. and Dinsart, C. (1987) *EMBO J.* T, 4193-4196.

30 30. Lefort, A., Lecocq, R., Libert, F., Lamy, F., Swillens, S., Vassart, G. and Dumont, J.E. (1989) *EMBO J.* 8, 111-116.

31. Koizumi, Y. et al. (1982), *Endocrinology*, Vol. 110, No. 4,pp. 1381-1391.

20 32. Clinical Abstract, (1981), Vol. 29, No.2, page 294A.

33. Valente, W.A. et al. (1982), *PNAS*, Vol. 79, pp.6680-6684


25 34. Hill, B.L. and Erlanger, B.F. (1988), *Endocrinology*, Vol. 122, No.6, pp.2840-2850.

35 WO87/05703

30 36 WO91/03483 (published 21 March 1991)

### Claims

35 1. A process for the preparation of a recombinant polypeptide possessing thyrotropin receptor activity, which polypeptide i) is characterised in that it comprises an amino-acid sequence represented by the following general formula:



40 wherein n = 0 or 1; m = 1; p = 0 or 1;  
 and X, Y and Z are defined as follows (using the one-letter amino-acid symbol and wherein a plurality of letters at any one site indicates the presence of any one of the given amino-acid residues at that site):



50 Y = at least the minimum number of consecutive amino-acids of the following sequence necessary for the presentation of immunogenic properties:

GGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLI  
 K P D H T F

5 ETHLRTIPSHAFSNLPNISRIYVSIDLTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPD  
 Q K R L A R M S S

10 ALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETL  
 GV V V A A

15 TLKLYNNNGFTSVQGYAFNGTKLDAYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTA  
 I H SA T Y

LPSKGLEHLKELIARNTWTLKKLPLSFLHLTRADLSYPHCCAFKNQKKIRGILESLM

20 CNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQE  
 IR T G FD Y HA DN Q DS S

25 DEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCED  
 L V GN

and Z = [I - II - II<sub>i</sub> - III - III<sub>i</sub> - IV - V - VI - VII] wherein the amino-acid sequences I - II - II<sub>i</sub> - III - III<sub>i</sub> - IV - V - VI - VII - VII<sub>i</sub> are independently present or absent and have the following meanings:

30 I = IMGYKFLRIVVWFVSLALLGNVFVLLILLTSHYK  
 IV

or at least 12 consecutive amino-acid residues of this sequence;

35 II = LNVPRFLMCNLAFADFCMGMYLLLIASVDLYTHSEYYNHA  
 T I I IH K Q H Y

40 or at least 12 consecutive amino-acid residues of this sequence;

45 II<sub>i</sub> = IDWQTGPGC  
 A

or at least 2 consecutive amino-acid residues of this sequence;

50 III = NTAGFFTVAESELVYTLVITL  
 DA

55 or at least 22 consecutive amino-acid residues of this sequence

III<sub>i</sub> = ERWYAITFAMRLD  
HT H Q

5 or at least 2 consecutive amino-acid residues of this sequence;

IV = RKIRLRHACAIMVGGWCCFLALLPLVGISSYAKVSICL  
C VQ YSV M IFA AA F IF M  
A

or at least 12 consecutive amino-acid residues of this sequence;

V = PMDTETPLALAYIVFVLTLNIVAFVIVCCCYVKIYITVRN  
      IDS SQL VIL L VL I S  
                  MSL V

or at least 12 consecutive amino-acid residues of this sequence;

25 VI = PQYNPGDKDTKIAKRMALIFTDFICMAPISFYALSAILNKPLIT  
M M

30 or at least 12 consecutive amino-acid residues of this sequence;

VII = VSNSKILLVLFYPLNSCANPFLYAIIFTKAFQRD  
T

or at least 12 consecutive amino-acid residues of this sequence:

40  
VII<sub>i</sub> =  
VFILLSKFGICKRQAQAYRGQRVPKNSTDIQVQKVTNDMRQGLHNMEDVYELIENS  
S AG I R S P Q E L  
45  
HLTPKKQGQISEEYMQTVL  
N K N

50 or at least 12 consecutive amino-acid residues of this sequence;

it being understood that any of the above-specified amino-acids can be replaced or deleted, and that extra amino-acid residues may be inserted provided the thyrotropin receptor activity is maintained, by the expression of a nucleic acid coding for the polypeptide in a host cell transformed by a vector in which said nucleic acid has been operationally inserted, and which polypeptide, ii) in the case of  $p = 1$ , further is characterized in that it is associated with such a host cell, the receptor thus being present in a non-thyroidal cellular environment, or with a membrane preparation which is free of impurities associated with detergent-solubilized thyroid membrane preparations.

2. Process according to claim 1, characterised in that the polypeptide "Y" is composed of at least one of the following sub-sequences: Y<sub>1</sub> to Y<sub>13</sub>:

5           Y<sub>1</sub>: GMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQT  
                  K    P                   D                    H    T

10           Y<sub>2</sub>: LKLIETHLRTIPSHAFSNLPNISR  
                  F    Q    K                   R

15           Y<sub>3</sub>: IYVSIDLTLQQLESHSFYNLSKVTH  
                  L    A    R                            M

20           Y<sub>4</sub>: IEIRNTRNLTYIDPDALKELPLLKF  
                  S    S

25           Y<sub>5</sub>: LGIFNTGLKMFPDLTKVYSTD~~IFFI~~  
                  GV    V                            V

30           Y<sub>6</sub>: LEITDNPYMTSIPVNAFQGLCNETL  
                  A    A

35           Y<sub>7</sub>: TLKLYNNNGFTSVQGYAFNGTKLDAV  
                  I    H

40           Y<sub>8</sub>: YLNKNKYLTVIDKDAFGGVYSGPS  
                  SA                                    T

45           Y<sub>9</sub>: LLDVSQTSVTALPSKGLEHLKELIA  
                  Y

Y<sub>10</sub>: RNTWTLKKLPLSLSFLHLTRADL

50           Y<sub>11</sub>: SYPSHCCAFKNQKKIRGILESLMCN

Y<sub>12</sub>: ESSMQSLRQRKSVNALNSPLHQEYE  
IR T G FD

5 Y<sub>13</sub>:

ENLGDSIVGYKEKSFKFQDTHNNAHYYVFFEEQEDEIIGFGQELKNPQEETLQAFDSH  
Y HA DN Q DS S L

10 YDYTICGDSEDMVCTPKSDEFNPCED  
V GN.

15 3. Process according to any of claims 1 or 2, in which the part of the polypeptide forming the transmembrane domain [Z] is heterologous to the TSH receptor, the polypeptide thus being a hybrid polypeptide.

4. Process according to claim 1, wherein the polypeptide is characterised by the sequence shown in fig. 11.

20 5. Nucleotide sequences coding for the polypeptide to be prepared according to the process of claims 1 to 4, and nucleotide sequences which are complementary to said sequences, provided that said nucleotide sequence is not the sequence contained in the clone tr.12.6-1 deposited under ATCC accession number 40651.

6. Nucleotide sequence according to claim 5, characterised in that the sequence is a DNA sequence having the sequence shown in fig. 5 or fig 12 or a sequence complementary to said sequences.

25 7. Use of intact cells obtained in a process according to claims 1 to 4, provided that p=1, in a process for the quantitative detection of TSH or of anti-TSHr antibodies, wherein said intact cells are contacted with the biological sample suspected of containing TSH or anti-TSHr antibodies and wherein in said intact cells the change in adenylyl cyclase activity is measured, for example by measuring c-AMP generation or release.

30 8. Use of intact cells obtained in a process in accordance with claim 1 to 4 according to claim 7, wherein the intact cells expressing the receptor polypeptide are contacted with the biological sample and, either simultaneously or subsequently with TSH, thereby allowing any inhibition of the adenylyl cyclase activating effect of TSH by "blocking" anti-TSHr antibodies present in the biological sample to be detected.

## Patentansprüche

40 1. Ein Verfahren zur Herstellung eines rekombinanten Polypeptids, das Thyrotropinrezeptor-Aktivität besitzt, wobei das Polypeptid (i) dadurch gekennzeichnet ist, daß es eine Aminosäuresequenz aufweist, die von der folgenden allgemeinen Formel wiedergegeben wird:

$$[X]_p - [Y]_m - [Z]_p$$

45 worin  $n = 0$  oder  $1$ ;  $m = 1$ ;  $p = 0$  oder  $1$ ;  
und  $X$ ,  $Y$  und  $Z$  wie folgt definiert sind (unter Verwendung des Einbuchstaben-Aminosäuresymbols und wobei eine Vielzahl von Buchstaben in irgendeiner Position die Anwesenheit von irgendeinem der angegebenen Aminosäureresten in dieser Position anzeigt):

X = MRPADLLQLVLLLDLPRDL  
PP H A A S

Y = wenigstens die Mindestanzahl von aufeinanderfolgenden Aminosäuren der nachfolgenden Sequenz, die erforderlich ist, daß Immunogen ein Eigenschaften verfügt.

GGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLI  
 K P D H T F

5 ETHLRTIPSHAFSNLPNISRIYVSIDLTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPD  
 Q K R L A R M S S

ALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETL  
 GV V V A A

10 TLKLYNNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTA  
 I H SA T Y

15 LPSKGLEHLKELIARNTWTLKKLPLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLM

CNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSFKQDTHNNAHYYVFFEEQE  
 IR T G FD Y HA DN Q DS S

20 DEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCED  
 L V GN

25 und Z = [I - II - II<sub>i</sub> - III - III<sub>i</sub> - IV - V - VI - VII - VII<sub>i</sub>] worin die Aminosäuresequenzen I - II - II<sub>i</sub> - III - III<sub>i</sub> - IV - V - VI - VII - VII<sub>i</sub> unabhängig voneinander vorhanden sind oder fehlen und die folgenden Bedeutungen aufweisen:

25

I = IMGYKFLRIVVWFVSLLALLGNVFVLLILLTSHYK  
 IV

30

oder wenigstens 12 aufeinanderfolgende Aminosäurereste aus dieser Sequenz;

35

II = LNVPRFLMCNLAFADFCMGMYLLLIAASVDLYTHSEYYNHA  
 T I I IH K Q H Y

40

II<sub>i</sub> = IDWQTGPGC  
 A

45

oder wenigstens 2 aufeinanderfolgende Aminosäurereste aus dieser Sequenz;

50

III = NTAGFFTVAFAESELSVYTLTVITL  
 DA

55

III<sub>i</sub> = ERWYAITFAMRLD  
 HT H Q

oder wenigstens 2 aufeinanderfolgende Aminosäurereste aus dieser Sequenz;

5           IV =           RKIRLRHACAIMVGGWVCCFLLALLPLVGISSYAKVSICL  
              C VQ        YSV        M IFA AA    F IF        M  
              A

10           oder wenigstens 12 aufeinanderfolgende Aminosäurereste aus dieser Sequenz;

15           V =           PMDTETPLALAYIVFVLTLNIVAFVIVCCCYVKIYITVRN  
              IDS   SQL VIL   L   VL   I   S  
              MSL V

20           oder wenigstens 12 aufeinanderfolgende Aminosäurereste aus dieser Sequenz;

25           VI =           PQYNPGDKDTKIAKRMALIFTDFICMAPISFYALSAILNKPLIT  
              M   LM

30           oder wenigstens 12 aufeinanderfolgende Aminosäurereste aus dieser Sequenz;

35           VII =           VSNSKILLVLFYPLNSCANPFLYAIIFTKAFQRD  
              T

40           oder wenigstens 12 aufeinanderfolgende Aminosäurereste aus dieser Sequenz;

45           VII<sub>i</sub> =  
              VFILLSKFGICKRQAQAYRGQRVPPKNSTDIQVQKVTHDMRQGLHNMEDVYELIENS  
              S   AG   I   R    S P   Q E   L  
              HLTPKKQQQIISSEYMQTVL  
              N           K   N

50           oder wenigstens 12 aufeinanderfolgende Aminosäurereste aus dieser Sequenz;

55           wobei gilt, daß irgendwelche der oben angegebenen Aminosäuren ersetzt werden oder entfallen können, und daß zusätzliche Aminosäurereste eingeschoben werden können, vorausgesetzt, daß die Thyrotropinrezeptor-Aktivität beibehalten wird,

60           durch Expression einer Nukleinsäure, die für das Polypeptid kodiert, in einer Wirtszelle, die durch einen Vektor transformiert wurde, in den die genannte Nukleinsäure operativ eingesetzt wurde,

65           und wobei das Polypeptid ii) im Falle von p = 1 außerdem dadurch gekennzeichnet ist, daß es mit einer derartigen Wirtszelle assoziiert ist, so daß der Rezeptor in einer nicht-thyroidalen zellulären Umgebung vorliegt, oder in einer Membranpräparation, die frei von Verunreinigungen ist, die mit Detergens-solubilisierten Schilddrüsenmembranpräparationen assoziiert sind.

2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß das Polypeptid "Y" aus wenigstens einer der folgenden

Untersequenzen  $Y_1$  bis  $Y_{13}$  zusammengesetzt ist:

5       $Y_1:$       GMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQT  
                  K    P                   D                   H    T

10      $Y_2:$       LKLIETHLRTIPSHAFSNLPNISR  
                  F    Q   K                   R

15      $Y_3:$       IYVSIIDLTLQQLESHSFYNLSKVTH  
                  L    A   R                   M

20      $Y_4:$       IEIRNTRNLTYIDPDALKELPLLKF  
                  S    S

25      $Y_5:$       LGIFNTGLKMFPDLTKVYSTDIFFI  
                  GV    V                   V

30      $Y_6:$       LEITDNPYMTSIPVNAFQGLCNETL  
                  A    A

35      $Y_7:$       TLKLYNNGFTSVQGYAFNGTKLDAV  
                  I    H

40      $Y_8:$       YLNKNKYLTVIDKDAFGGVYSGPS  
                  SA                           T

45      $Y_9:$       LLDVSQTSVTALPSKGLEHLKELIA  
                  Y

50      $Y_{10}:$      RNTWTLKKLPLSLSFLHLTRADL

45      $Y_{11}:$      SYPHCCAFKNQKKIRGILESLMCN

55      $Y_{12}:$      ESSMQSLRQRKSVNALNSPLHQEYE  
                  IR                   T    G   FD

50      $Y_{13}:$      ENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQEDEIIGFGQELKNPQEETLQAFDSH  
                  Y    HA    DN   Q    DS   S                   L

55      $Y_{13}:$      YDYTICGDSEDMVCTPKSDEFNPCED  
                  V    GN.

3. Verfahren nach irgendeinem der Ansprüche 1 oder 2, bei dem der Teil des Polypeptids, der die Transmembran-Domäne [Z] bildet, zu dem TSH-Rezeptor heterolog ist, so daß das Polypeptid ein Hybrid-Polypeptid ist.

4. Verfahren nach Anspruch 1, bei dem das Polypeptid durch die Sequenz charakterisiert ist, die in Figur 11 gezeigt ist.

5. Nukleotidsequenzen, die für das nach dem Verfahren der Ansprüche 1 bis 4 herzustellende Polypeptid kodieren, sowie Nukleotidsequenzen, die zu diesen Sequenzen komplementär sind, vorausgesetzt, daß die genannte Nukleotidsequenz nicht die Sequenz ist, die in dem Klon tr.12.6-1 enthalten ist, der unter ATCC-Hinterlegungsnummer 40651 hinterlegt ist.

10. Nukleotidsequenz nach Anspruch 5, dadurch gekennzeichnet, daß die Sequenz eine DNA-Sequenz ist, die die Sequenz aufweist, die in Figur 5 oder Figur 12 gezeigt ist, oder eine Sequenz, die zu diesen Sequenzen komplementär ist.

15. Verwendung von intakten Zellen, die nach einem Verfahren gemäß den Ansprüchen 1 bis 4 erhalten werden, wenn  $p = 1$ , in einem Verfahren für den quantitativen Nachweis von TSH oder von Anti-TSHr-Antikörpern, wobei die genannten intakten Zellen mit der biologischen Probe in Kontakt gebracht werden, von der vermutet wird, daß sie TSH oder Anti-TSHr-Antikörper enthält, und wobei in den genannten intakten Zellen die Veränderung der Adenylylcyclase-Aktivität gemessen wird, beispielweise durch Messung der c-AMP-Erzeugung oder -Freisetzung.

20. Verwendung von intakten Zellen, die in einem Verfahren gemäß Anspruch 1 bis 4 erhalten werden, gemäß Anspruch 7, wobei die intakten Zellen, die das Rezeptor-Polypeptid exprimieren, mit der biologischen Probe in Kontakt gebracht werden und entweder gleichzeitig oder anschließend mit TSH, wodurch man eine Inhibition des Adenylylcyclase-aktivierenden Effekts von TSH durch "blockierende" Anti-TSHr-Antikörper ermöglicht, die in der zu untersuchenden biologischen Probe vorhanden sind.

25.

#### Revendications

30. 1. Procédé de préparation d'un polypeptide recombinant possédant une activité de récepteur de la thyrotropine, lequel polypeptide i) est caractérisé en ce qu'il comprend une séquence d'acides aminés représentée par la formule générale suivante :

$$[X]_n - [Y]_m - [Z]_p$$

35. dans laquelle  $n = 0$  ou  $1$ ,  $m = 1$ ,  $p = 0$  ou  $1$ ,

et  $X$ ,  $Y$  et  $Z$  sont définis de la manière suivante (à l'aide des symboles d'acides aminés à une lettre et une multiplicité de lettres à un site quelconque indiquant la présence à ce site de l'un quelconque des résidus d'acides aminés donnés) :

40.  $X = \text{MRPADLLQLVLLLDLPRDL}$

45.  $\text{PP H A A S}$

50.  $Y =$  au moins le nombre minimum d'acides aminés consécutifs de la séquence suivante nécessaire pour la présentation des propriétés immunogènes :

GGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLI

K P D H T F

5

ETHLRTIPSHAFSNLPNISRIYVSIDLTLQQLESHSFYNLSKVTHIEIR

Q K R L A R M

10

NTRNLTYIDPD

S S

15

ALKELPLLKFLGIFNTGLKMFPLDTKVYSTDIFFILEITDNPYMTSI

GV V V A

20

PVNAFQGLCNETL

A

25

TLKLYNNNGFTSVQGYAFNGTKLDAYLNKNKYLTVIDKDAFGGVYSGPS

I H SA T

30

LLDVSQTSVTA

Y

LPSKGLEHLKELIARNTWTLKKLPLSFLHLTRADLSYPHCCAFKNQKKI

35

RGILESML

CNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNA

IR T G FD Y HA DN Q DS S

45

HYYVFFEEQE

DEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCED

L V GN

50

et Z = [I - II - II<sub>i</sub> - III - III<sub>i</sub> - IV - V - VI - VII - VII<sub>i</sub>] où les séquences d'acides aminés I - II - II<sub>i</sub> - III - III<sub>i</sub> - IV - V - VI - VII - VII<sub>i</sub> sont indépendamment présentes ou absentes et ont les significations suivantes :

55

I = IMGYKFLRIVVWFVSSLALLGNVFVLLILLTSHYK

IV

ou au moins 12 résidus d'acides aminés consécutifs de cette séquence ;

II = LNVPRFLMCNLAFADFCMGMYLLIASVDLYTHSEYYNHA  
T I I IH K Q H Y

ou au moins 12 résidus d'acides aminés consécutifs de cette séquence ;

II<sub>j</sub> = IDWQTGPGC  
A

ou au moins 2 résidus d'acides aminés consécutifs de cette séquence ;

III = NTAGFFTVAFAESEL SVYTLTVITL  
DA

ou au moins 22 résidus d'acides aminés consécutifs de cette séquence ;

III<sub>1</sub> = ERWYAITFAMRLD  
HT H O

ou au moins 2 résidus d'acides aminés consécutifs de cette séquence :

IV = RKIRLRHACAIMVGGWVCCFLALLPLVGISSYAKVSICL  
C VQ YSV M IFA AA F IF M  
A

ou au moins 12 résidus d'acides aminés consécutifs de cette séquence :

V = PMDTETPLALAYIVFVLTLNIVAFVIVCCCYVKIYITVRN  
IDS SQL VIL L VL I S  
MSL V

ou au moins 12 résidus d'acides aminés consécutifs de cette séquence ;

VI = PQYNPGDKDTKIAKRMAVLIFTDFICMAPISFYALSAILNKPLIT  
M LM

ou au moins 12 résidus d'acides aminés consécutifs de cette séquence ;

VII = VSNSKILLVLFYPLNSCANPFLYAIFTKAFQRD

T

5

ou au moins 12 résidus d'acides aminés consécutifs de cette séquence ;

10 VII<sub>i</sub> = VFILLSKFGICKRQAQAYRGQRVPPKNSTDIQVQKVTHDMRQ  
S      AG    I      R

10

15 GLHNMEDVYELIENSHLTPKKQGQISEEYMQTVL

S    P    Q    E    L    N    K    N

15

ou au moins 12 résidus d'acides aminés consécutifs de cette séquence ;

20 étant entendu que l'un quelconque des acides aminés spécifiés ci-dessus peut être remplacé ou délégué et que  
des résidus d'acides aminés supplémentaires peuvent être insérés à condition que l'activité de récepteur de  
la thyrotropine soit maintenue, par l'expression d'un acide nucléique codant le polypeptide dans une cellule  
hôte transformée par un vecteur dans lequel ledit acide nucléique a été inséré de manière active,  
25 et lequel polypeptide, ii) dans le cas où p = 1 et caractérisé encore en ce qu'il est associé à une telle cellule  
hôte, le récepteur étant ainsi présent dans un environnement cellulaire non thyroïdien, ou à une préparation  
de membranes qui est dépourvue d'impuretés associées aux préparations de membranes thyroïdiennes sta-  
bilisées par des détergents.

30 2. Procédé selon la revendication 1, caractérisé en ce que, dans le polypeptide, "Y" est composé d'au moins l'une  
des sous-séquences suivantes :

35

40

45

50

55

Y<sub>1</sub> : GMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQT

K P D H T

5

Y<sub>2</sub> : LKLIETHLRTIPSHAFSNLPNISR

F Q K R

10

Y<sub>3</sub> : IYVSIIDLTLQQLESHSFYNLSKVTH

L A R M

15

Y<sub>4</sub> : IEIRNTRNLTYIDPDALKELPLLKF

S S

20

Y<sub>5</sub> : LGIFNTGLKMFPDLTKVYSTD~~Y~~IFI

GV V V

25

Y<sub>6</sub> : LEITDNPYMTSIPVNAFQGLCNETL

A A

30

Y<sub>7</sub> : TLKLYNNNGFTSVQGYAFNGT~~K~~DAV

I H

35

40

45

50

55

5

Y<sub>9</sub> : LLDVSQTSVTALPSKGLEHLKELIA  
Y

10

Y<sub>10</sub>: RNTWTLKKLPLSLSFLHLTRADL

15

**Y<sub>11</sub>** : SYP SHCC AFKNQ KKIR GILESL MCN

20

Y12: ESSMQSLRQRKSVNALNSPLHQEYE  
IR T G FD

Y<sub>13</sub>: ENLGDSIVGYKEKSKFQDTHNNAHYYFEEQEDEIIGFG  
X HA DN Q DS S L

25

QELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCED  
V GN

30

3. Procédé selon l'une quelconque des revendications 1 ou 2, dans lequel la partie du polypeptide formant le domaine transmembranaire [Z] est hétérologue au récepteur de la TSH, le polypeptide étant ainsi un polypeptide hybride.

35 4. Procédé selon la revendication 1, dans lequel le polypeptide est caractérisé par la séquence représentée sur la figure 11.

40 5. Séquences nucléotidiques codant le polypeptide destiné à être préparé selon le procédé des revendications 1 à 4, et séquences nucléotidiques qui sont complémentaires desdites séquences, à condition que ladite séquence nucléotidique ne soit pas la séquence contenue dans le clone tr.12.6-1 déposé sous le numéro de dépôt ATCC 40651.

45 6. Séquence nucléotidique selon la revendication 5, caractérisée en ce que la séquence est une séquence d'ADN ayant la séquence représentée sur la figure 5 ou la figure 12 ou une séquence complémentaire desdites séquences.

50 7. Utilisation de cellules intactes obtenues dans un procédé selon les revendications 1 à 4, à condition que  $p = 1$ , dans un procédé de détection quantitative de la TSH ou d'anticorps anti-TSHr, dans laquelle lesdites cellules intactes sont mises en contact avec l'échantillon biologique supposé contenir de la TSH ou des anticorps anti-TSHr et dans laquelle, dans lesdites cellules intactes, la variation d'activité d'adénylate cyclase est mesurée, par exemple par mesure de la production ou de la libération d'AMPc.

55 8. Utilisation selon la revendication 7 de cellules intactes obtenues dans un procédé selon les revendications 1 à 4, dans laquelle les cellules intactes exprimant le polypeptide du récepteur sont mises en contact avec l'échantillon biologique et, simultanément ou successivement, avec de la TSH, pour permettre ainsi la détection de toute inhibition de l'effet activant l'adénylate cyclase de la TSH par des anticorps anti-TSHr "bloquants" présents dans l'échantillon biologique.

1

3rd transmembrane segment

HOMPO9	CDA AOPFTVFASKLSVYLTIAITL ERWHTITHAMQLDCKVQLRHAASVMNG-WIFAF
M2HUM	* * * * *
M3HUM	CDL WLADDYVVSNA SVMNLLIISF DRYFCVTKPLTYPVRTKMGMMIAA-WVLF
M4HUM	CDL WLADDYVVSNA SVMNLLIISF DRYFCVTKPLTYPARRTKMAGLMIAA-WVLF
ALADRHAM	CDL WLADDYVVSNA SVMNLLIISF DRYFSVTRPLSYRAKTPRRAALMIGLA-WVLF
D2R	CDI FVLDVMMCTASILSICAI SY DRYIGVRSLOVPTLVTRRKAILALLSV-WVLF
BLADRHUM	CRL WTSVBDVLCVTA SIRTLCVIAV DRYLAITSPPYQSLLTTRABRGVCT-WAIS
B2ADRHUM	CRF WTSVBDVLCVTA SIRTLCVIAV DRYLAITSPPYQSLLTTRABRGVCT-WAIS
BADRHAM	CDI WLSIDVLCVTA SIRTLCVIAV DRYMAITSPFKYQSLLTTRKARVILMV-WIVS
RDC4	CDI WLSIDVLCVTA SIRTLCVIAV DRYMAITSPFKYQSLLTTRKARVILMV-WIVS
A2ADRHUM	CRF WLADDVLFCTSSIVHLCAISL DRYWSITQAIEYNKTRRRAKALIC-WVSA
Q216HTA	CDL FIALDVLCCTS8IHLCAISL DRYWAITDPIDYVMKTP-RPRAALSLT-WLIF
6HTICRAT	CPV WISLDVLFSTASIMHLCAISL DRYVAIRNPPIERHSRFNSRTKAIMKIAIV-WAISI
6HT2R	CAI WIYLDVLFSTASIMHLCAISL DRYVAIQNPINHSRFNSRTKAFKIIAV-WTISV
RDC8	CLF PACFVVLVLTOSISISSLIAI DRYIAIRIPRLYNGLVTQTRAKQIAC-WVLF
RDC7	CLM VACPVVLITQSSILALLIAV DRYLRVQKIPRLYKTUTPRRAAVIAIGC-WILF
SKRBOV	CFV QNLFPITAMFVSIYSMATAIA DRYMAIVHPFQP--RLSAPOTRAVIGI-WLVAL
RDC1	CKI THLFSINLPGSIFFLCMSV DRYLSITYPASTSSRKKVVRRAVCVLV-WLAF

^ ^

**THIS PAGE BLANK (USPTO)**

2a

七

8

DOOTSH : **MEPPPLILHALLALPES** — **LOGLOCSPPOCCHEODDFRUTCKDIERHITPLPSTOTMLPIKTOLT** — **PSRASNLPMISHEMLSDATO**  
RATCO : **MORVPLALRUVLAVLILMPSOLSRHLSASRSCPT-POCAGDML** — **RECPORHMLAHLSTLVLPUKVITSGABRMLNVEVKRISODSL**  
PITRON : **MEBBSWIR-TLAVLWUPPPIROT-LIACPCE-POSCHEPDOL** — **RECPORHMLAHLSTLVLPIKVIQSARHMLNVEVKRISODSL**

10

三

200. *STOCHASTIC DYNAMIC PROGRAMMING AND CONTROL OF LINEAR SYSTEMS* 260.

—KIRKILES LÄCKES SJÖRS LÄCKES SVN—TLMPTDÖR VETV TGSWMTDINSQPTDTSNSHVVTFHÖRDEI LÄRÖR KUNPÖRTLÄDSDHYT 300. 350.

RATHOC : KEROMPSISPIRNESKOCESTVAKADNETLYSAIPAKENKLSDW  
PIGHO : TURONPSISPIANFSKOCESTVAKADNETLYSAIPAKENKLSDW  
YDYG  
\*\*\*

VOGNNKNDVCTPKMDEFNPFCDIMKFLRIVWVFLSLLANVFLVLITSHMLTVPRFLACINLATADPOCMVLLASVOLYTHRYTHYHADM  
400. I II 460.

RATIO : PUSPKT-LOCAPRDPDAFPCKHNUKIVLAKLWILWLNLAINGV  
PIGSKC : PUSPKT-LOCAPRDPDAFPCKHNUKIVLAKLWILWLNLAINGV  
WOMEN : IGYILLLASVDTHTSQHRYVADWW

DOUTSH : OTUPOONTADIFTVASEISUVTITVILBRYAITFAMRLDKEKILMAYAIDNGWVCCFLALIPIROISSYAKSICLIPOTPLAIVLW  
RATREX : OTASOCOQADIFTVASEISUVTITVILBRYAITFAMRLDKEKILMAYAIDNGWVCCFLALIPIROISSYAKSICLIPOTPLAIVLW

650. VI 650. VII

LNIVAFVVICACTYVTAVONPEKIMATKOTKIAKRMVLLIDTCAPLSFIAALKVPLITVSKVLLVFTYVNSCANPFLYVLAITMARE

DOGSTH : VFILSKRICKRQAQYRQRSVSP— KNSAQIQIAVTRMDSLSPLMADYBLLENSHTPJKRQOISKEVNTVL  
RATHCO : PULLSARTOOCKHARLTYRMRFSAYTSKCKWIPRASPSQNTLSTTMCOPIPRALTH  
PIGNO : PULLSARTOOCKHARLTYRMDFSAY— CNOHFTUSMAPSBLTLLTACOYSTMDKTCYC


卷之三

600

28

**THIS PAGE BLANK (USPTO)**

Fig 26




**THIS PAGE BLANK (USPTO)**

# Best Available Copy


EP 0 433 509 B1

Fig 3a




**THIS PAGE BLANK (USPTO)**

Fig 3b



**THIS PAGE BLANK (USPTO)**

Fig 4



**THIS PAGE BLANK (USPTO)**


-62

1 CAAGGCGCCGCCGCCCTGCTGC ACCTGGCGCTCTGGGA TGAAGAAA TACCCCTGGACCCCTGGAAA  
 91 TCC ACC AGG AGG ATG ACT TC AGAGTC ACCTGC ACGGAT ATCC ACCCAC ATCCC ACCTTACCAACCC AGC AGC AGACTCTGAA  
 181 GAGACTC AGCTGAAAACCATTGCCAGTCGTOCATTTCAAAATCTGCCAAATTTCAGGATCTACTGTCAATAGATGAACTCTGAG  
 271 CGCTGGATCTACATTCCTCTACATTAAAGTAAATGACTCACAATAGAGTTGGAAATCCAGAAGCTTAAACATCCATAGACCTGAC  
 361 GCGCTAAAAGAAGCTCCGACTCTGAAAGTTCTGCAATTTCACACTGACTTCACTTCCAGGATCTGAAACATCCAGGCTGAC  
 451 GATGTATCTTAACTTCAATACAGACACCGCTACATGGCTCAGTCCAGGCTGAGGATCTGAGCTGAACTTCAATGAAAGCTG  
 541 ACAGTGAACCTATACAAACAAACGATCTGAAAGTAAAGTAAAGGAGCTGAGCTGAGGACCACTCTGAGTGTCTCTTACACCAGTGAACTG  
 631 AAATACCTGTCAGCTATGAGGAGCTGAGTGTGAAACACTTGGACTTAAAGGAACTTAAAGGAACTTAAAGGAACTTAAAGGAACTTAAAGGAA  
 721 CTGCGATCCAAAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG  
 811 CACCTTACACCGGCTGACCTTCTGATCCAAAGGACACTGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG  
 901 TGTAAATGAAAGGACTATTCGGAGGCTGCGAGAGAAAATCTGTGAAATACTTTGAAAGGCGCTTGGACCAAGGATATGAAAGGATATCTG  
 991 CCTGACAGCCATGCTGGGTAACAGGACAACTCTGCACTTCTGAAAGGAGCCAACTCTGCTTAAATATGCTCTTGGAAAGGAAAGGAA  
 1081 GATGAGAACTGCTGGGTTGGGAGGAACTTAAAGGACAACTCTGCACTTCTGCACTTCTGAGGACAACTCTGAGGAACTTAAAGGAAAGGAA  
 1171 CCTGCGATCTGAAAGGAACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG  
 1261 GTCTGTTG  
 1351 TTCTGCACTGCGACTTGGGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 1441 TACTACAAACATGCCATGACTGAGACAGCAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 1531 ACAGTGAAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 1621 ATCATGGTTGGGGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCG  
 1711 CCATGAGACACTGAGACACCTCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTGCGCTG  
 1801 TATGTCAGAGATCTACATGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 1891 TTCACTGACTTCACTGCGATGCGCCAACTCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 1981 ATCTTCTGTT  
 2071 ATCCCTGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 2161 ATCCAAAGGTTACCGCGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 2251 AAGCAGGCGAACTCTCAAGAGTAAACCAACAGTCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 2341 TAGTTCTGAACTGAGTATCCAAATTCAATATACACAGAGACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 2431 TCTGCAAAAGGGTGAAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 2521 ATAACTGACACTTCTGAGAACTTCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 2611 AACATTGAGCTCTGAGCTTCAAAATGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 2701 GAATTAAAGGCGATGTT  
 2791 GATACATGCGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 2881 TCAACAAAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 2971 AGTAAGAACTGCTCTTCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 3061 CAAGGCGACACTAAATCACACACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 3151 TAGAAAATGAGAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 3241 AAGCTAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAA  
 3331 CCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 3421 AAATCACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 3511 TGCAAATTTGGTTATTCAGAGTACTCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 3601 CTGAGCTAAAGAACACTAAAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 3691 CCTTAACTTCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 3781 CCTTAACTTCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 3871 TGTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 3961 CTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 4051 TAACTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 4141 GAAATAACACTTCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 4231 CTATGAAATGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAG  
 4321 GACAGGCGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAAAGGAA

Fig 5

**THIS PAGE BLANK (USPTO)**

Fig 6.



**THIS PAGE BLANK (USPTO)**

Fig 7

-20    *MRPPPLIHLALLALPRSLG*  
 1    *GKGCPSPPCCEHQEDDFRVTCKDIHRIPTLPPSTQT*  
 37    *LKF-IETOLKTIPSRAFSNLPNISR*  
 61    *IYLSIDATLQRLESHSFYNLSKMTH*   
 86    *IEIRNRTSLSLTSIDPDALKELPLLKF*  
 111    *LGIFNTGLGVFPDVTKVYSTDVFFI*  
 136    *LEITDNPYMASIPANAFQGLCNETL*  
 161    *TLKLYNNNGFTSIQGHAFNGTKLDAV*  
 186    *YLN-KNKYLSAIDKDAFGGVYSGPT*  
 210    *LLDVSYTSVTALPSKGLEHLKELIA*  
 235    *RNTWTLKKLP-L-SLSFLHLTRADL...*  
 Cons    *L L I X X N X X L X S I P S X A F X G L X X X X*  
       *I T            ALD    S*

**THIS PAGE BLANK (USPTO)**


Fig 8

## Comparison of human and dog TSH receptor sequences

	-20	1	20	40	
Human TSHR :	MRPADLQLVLLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPS	LPPSTQTLKLI			
Dog TSHR :	PP H A A S K P	D	H T	F	
	60	80	100		
Human TSHR :	ETHLRTIPSHAFSNLP <u>NISRIYVSIDLT</u> IQQLES <u>HSFYNL</u> SKVTHIEIRNTRNLTYIDPD				
Dog TSHR :	Q K R L A R		M	S S	
	120	140	160		
Human TSHR :	ALKELPLL <u>FLGIF</u> NTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFOGLCNETL				
Dog TSHR :	GV V V		A A		
	180	200	220		
Human TSHR :	TLKLYNNNGFTSVQGYAF <u>NGTKLD</u> AVYLN <u>NKYLTV</u> IDKA <u>FGGVYSGPS</u> LLDV <u>SQTSVTA</u>				
Dog TSHR :	I H SA		T Y		
	240	260	280		
Human TSHR :	LPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYP <u>SECCAF</u> KNQKKIRGILESLM				
Dog TSHR :					
	300	320	340		
Human TSHR :	<u>CNESSMQSLRQRKS</u> VNALNSPLHQEYEENL <u>GDSIV</u> GYKEKSKFQDTHNNAHYYVFFEEQE				
Dog TSHR :	IR T G FD Y HA DN Q DS S				
	360	380	400		
Human TSHR :	DEIIIGFGQELKNPQEETLQAFDSHYDYTICGDSED <u>MV</u> CTPKSDEFN <u>PCED</u> IMGYRFLRIV				
Dog TSHR :	L V GN				
	I	420	440	II	460
Human TSHR :	<u>VWFVSL</u> ALLGNVFULLL <u>LTSHY</u> KLNVPR <u>FLMCN</u> LAFAD <u>FCMG</u> YLLIASVDLYTHSE				
Dog TSHR :	IV T				
	480	500	520		
Human TSHR :	YYNHAIDWQTGPGCNTAG <u>FFT</u> VFA <u>SEL</u> SVT <u>LT</u> VITLERWYAIT <u>FAM</u> RLDRKIRL <u>RHACA</u>				
Dog TSHR :				Y	
	IV	540	560	V	580
Human TSHR :	<u>IMVGGWVCC</u> FLLALLPLVG <u>ISSYAKV</u> SICLPM <u>DTET</u> PLALAYIV <u>FV</u> LT <u>LN</u> IVAFVIV <u>CCC</u>				
Dog TSHR :			IL L	I S	
	600	620	640		
Human TSHR :	<u>YVKIYITVRNP</u> QYNPG <u>DKDTKIAK</u> EMAVL <u>IFTDFICMAP</u> ISFYALS <u>SAILNK</u> PLIT <u>VNS</u> SK				
Dog TSHR :	M IM T				
	VII	660	680	700	
Human TSHR :	<u>ILLVL</u> FYPLN <u>SCANP</u> FLYAI <u>FTKAF</u> QRD <u>V</u> FILL <u>SKFG</u> ICKR <u>QAQAY</u> RGQR <u>VPP</u> KN <u>STD</u> IQ				
Dog TSHR :	S AG				
	720	740			
Human TSHR :	VQKVTHDMR <u>QGLHN</u> MDV <u>YELIEN</u> SHTPKK <u>QQ</u> Q <u>IS</u> <u>KEY</u> <u>M</u> TVL				
Dog TSHR :	I R S P Q E L N K N				


**THIS PAGE BLANK (USPTO)**

Fig 9



**THIS PAGE BLANK (USPTO)**

Fig 10



**THIS PAGE BLANK (USPTO)**

-20 1 20 40  
 MRPADLLQLVLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPSLLPPSTQTLKL  
 PP H A A S K P D H T F

60 80 100  
 ETHLRTIPSHAFSNLPNSRIYVSIDLTQQLEHSFYNLSKVTHEIRNTRNLTIDPD  
 Q K R L A R M S S

120 140 160  
 ALKELPLLKFLGIFNTGKLMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFOGLCNETL  
 GV V V A A

180 200 220  
 TLKLYNNNGFTSVOGYAFNGTKLDAVLNKYLTVIDKAFGGVSGPSILDVSQTSVTA  
 I H SA T Y

240 260 280  
 LPSKGLEHLKELIARNTWLKKLPLSLSFIHLTRADLSYPHCCAFKNOKKIRGILESML

300 320 340  
CNESSMOSLROKSVNANSPLHOEYEENLGDSIVGYKESKFQDTENNAHYVFEEQ  
 IR T G FD Y HA DN Q DS S

360 380 400  
 DEIIIGFGQELKNPGEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEIMGYKFLRIV  
 L V GN

420 440 460  
VWFVSLALGNVFVLLILLTSHKLNVPRFLMNLAFDCMGYLLIASVDLYTHES  
 IV T I I IH K Q

480 500 520  
 VYNHAIDWQTGFGCNTAGFFTVFASELSVTLTVITLEWAITFAMRLRKIRRHA  
 H Y A DA HT H Q C VQ Y S A

540 560 580  
IMVGGWVCCFLLLPLVGISSYAVSICLPMDTETPLAYIVFVLTNVAFVVCC  
 V M IFA AA F IF M IDS SQL VIL L VL I S MSL V

600 620 640  
 YVKIYIITVRNPOYNPGDKDTKIAKRMVLAIFTDFICMAPISFYALSAILNKPLITVNSK  
 M IM T

660 680 700  
 : ILLVLF7PLNSCANPFLYAIIFTXAFORDVFILLSEFGICKRQAQAYRGQRVPPKNSTDIQ  
 : S AG

720 740  
 : VQKVTHDMROGLRNMEDVYELIENSHLTPKKOCQIISSEYOMTVL  
 : I R S P Q E L N X N

Fig 14

**THIS PAGE BLANK (USPTO)**

Fig 12

10	20	30	40	50	60	70
5' ABBGAGCAGTTCTCTGGGACCTGATGGCTCCAGATCACTATCTGGGCCAGACTTCTGGAGCTG						
80 90 100 110 120 130 140						
AATCTCCAGTTGCTCGGGAGCCTCCTCAGACTCAGTGTGGCCAGAATGGTGGTCTGGCTTCCCTCGGG						
150 160 170 180 190 200 210						
CCTGCCCCCTTCTGCTGAGATGGTCATCAGCTTTCTCCCACTGCTGCCCTGTATGCA						
220 230 240 250 260 270 280						
GGGAAGGCGCTGCTGTGATCTGTAGTACTTCTGAAATGTGTTCTCTCCCCAGGGCCAGAGCT						
290 300 310 320 330 340 350						
GAGAATGAGGCGATTTCGGAGGATGGAGAAATAGCCCCGAGTCCCGTGGAAAATGAGGCCGGGACTTG						
360 370 380 390 400 410 420						
CTCCAGGTGGTGGCTGCTGACCTGCCCCAGGGACCTGGGCGGAATGGGGTGTCTCCACCCCTGCG						
430 440 450 460 470 480 490						
AGTGCCATCAGGAGGAGCTTCAGAGTCACCTCAAGGATATTCAACGCACTCCCCAGCTTACCGCCAG						
500 510 520 530 540 550 560						
TACGAGACTTGAAGCTTATTGAGACTCACCTGAGAACTATTCCAAGTCATGCATTCTAATCTGCC						
570 580 590 600 610 620 630						
ATATTTCCAAATCTACGTATCTATAGATCTGACTCTGAGCAGCTGGAATCACACTCCTCTACAATT						
640 650 660 670 680 690 700						
TGAGTAAAGTGAATCACATGAAATTGGATAACCAGGAACCTAACATAGACCTGATGCCCTCAA						
710 720 730 740 750 760 770						
AGAGCTCCCCCTCTAAAGTTCTGGCATTTCACACTGGACTTAAATGTTCCCTGACCTGACCAAA						
780 790 800 810 820 830 840						
GTATTCTCACTGATATATTCTTATACTTGAAATTACAGACAAACCTTACATGACGTCAATCCCTGTGA						
850 860 870 880 890 900 910						
ATGCTTTTCAAGGACTATGCAATGAAACCTTGACACTGAAAGCTGTACAAACAATGGCTTACTTCAGTCCA						
920 930 940 950 960 970 980						
AGEATATGCTTCAATGGGACAAAGCTGGATGCTGTTACCTAAACAAGAATAAAACTGACAGTTATT						
990 1000 1010 1020 1030 1040 1050						
GACAAAGATECATTGGAGGAGTATACTGGACCAAGCTGCTGGACGTGTCTCAAAACCGAGTGTCACTG						
1060 1070 1080 1090 1100 1110 1120						
CCCTTCCATCCAAGGGCTGGAGCACCTGAAGGAACCTGATGAGCAAGAAACACCTGGACTCTTAAGAAACT						
1130 1140 1150 1160 1170 1180 1190						
TCCACTTCTTGAGTTCTTCACCTCACACGGGCTGACCTTCTTACCCAAGCCACTGCTGTGCTTT						
1200 1210 1220 1230 1240 1250 1260						
AAGAATCAGAAGAAAATCAGAGGAATCCTTGAGTCCTGATGTGAATGAGAGCAGTATGCAAGAGCTTGC						
1270 1280 1290 1300 1310 1320 1330						
GCCAGAGAAAATCTGTGAATGCCTTGAATAGCCCCCTCCACCAGGAATATGAAGAGAACTGGGTGACAG						
1340 1350 1360 1370 1380 1390 1400						
CATTGTTGGGTACAAGGAAAAGTCCAAGTCCAGGATACTCATAACAAACGCTCATTATTACGTCTTCTT						
1410 1420 1430 1440 1450 1460 1470						
GAAGAACAAAGAGGATGAGATCATTGGTTGGCCAGGAGCTCAAAACCCCCAGGAAGAGACTCTACAAG						
1480 1490 1500 1510 1520 1530 1540						
CTTTGACGCCATTATGACTACACCATATGTGGGGACAGTGAAGACATGGTGTGACCCCCAAGTCCGA						
1550 1560 1570 1580 1590 1600 1610						
TGAGTTCAACCCGTTGAGACATAATGGGCTACAAGTCTGAGAATTGTTGGTGTGGCTTACGTCTG						
1620 1630 1640 1650 1660 1670 1680						
CTGGCTCTCTGGCAATGTCTTGTCTGCTTATTCTCCTCACCAAGCCACTACAAACTGAACGTC						
1690 1700 1710 1720 1730 1740 1750						
GCTTCTCATGTGCAACCTGGCCTTGTGGGATTTCTGACGGATGACCTGCTCTCATGCCCTGT						

**THIS PAGE BLANK (USPTO)**

Fig 12 Suite

1760	1770	1780	1790	1800	1810	1820
AGACCTCTACACTCACTCTGAGTACTACAACCATGCCATCGACTGGCAGACAGGGCCCTGGGTGCAACACG						
1830	1840	1850	1860	1870	1880	1890
GCTGGTTCTTCACTGTCTTGCAAGCGAGTTATCGGTGTTACGCTGACGGTCATCACCCCTGGAGCGCT						
1900	1910	1920	1930	1940	1950	1960
GGTATGCCATCACCTCGCCATGCCCTGGACCGGAAGATCCGCCCTAGGCACGCATGTGCCATCATGGT						
1970	1980	1990	2000	2010	2020	2030
TGGGGGCTGGGTTTGCTGCTTCCTCTGCCCTGCTTCCTTGGTGGGAATAAGTAGCTATGCCAAAGTC						
2040	2050	2060	2070	2080	2090	2100
AGTATCTGCCCTGCCCATGGACACCGAGACCCCTCTGCTCTGGCATATATTGTTTTGTTCTGACGCTCA						
2110	2120	2130	2140	2150	2160	2170
ACATAGTTGCCCTCGTCATCGTCTGCTGTTATGTGAAGATCTACATCACAGTCCGAAATCCGCAGTA						
2180	2190	2200	2210	2220	2230	2240
CAACCCAGGGGACAAAGATACCAAAATTGCCAAGAGGATGGCTGTGTTGATCTCACCGACTTCATATGC						
2250	2260	2270	2280	2290	2300	2310
ATGGCCCCAATCTCATTCTATGCTCTGTCAGCAATTCTGAACAAGCCTCTCATCACTGTTAGCAACTCCA						
2320	2330	2340	2350	2360	2370	2380
AAATCTTGCTGGACTCTCTATCCACTTAACCTCTGTGCCAATCCATTCTCTATGCTATTTTCAACCAA						
2390	2400	2410	2420	2430	2440	2450
GGCCTTCCAGAGGGATGTGTTCATCCTACTCAGCAAGTTGGCATCTGTAACACGCCAGGGCTCAGGCATAC						
2460	2470	2480	2490	2500	2510	2520
CGGGGGCAGAGGGTCTCCTCAAAGAACAGCACTGATATTAGGTTCAAAAGGTTACCCACGACATGAGGC						
2530	2540	2550	2560	2570	2580	2590
AGGGTCTCCACAACATGGAAAGATGTCTATGAACTGATTGAAAACCTCCCATCTAACCCCCAAAGAACAGCAAGG						
2600	2610	2620	2630	2640	2650	2660
CCAAATCTCAGAAGAGTATATGCCAACGGTTTGTAAGTTAACACTACACTCACAATGCTAGGGGAA						
2670	2680	2690	2700	2710	2720	2730
CTTACAAAATAATAGTTCTTGAATATGCAATTCCAAATCCCATGACACCCCCAACACATAGCTGCCCTCAC						
2740	2750	2760	2770	2780	2790	2800
TCTTGTGCAGGCAGTGTTCATGGGGCAAGAGTTATCTCTGGAGAGTGTATTAGTATTAAACC						
2810	2820	2830	2840	2850	2860	2870
TAATCATTGCCCTCAAAGAACAGGAAAGTTAGGCTACCAAGCATATTGAAATGCCAGGTGAAATCAAAATAATCT						
2880	2890	2900	2910	2920	2930	2940
ACACTATCTAGAAGACTTTCTGATGCCAAGTCCAGAGATGTCATTGTTAGGATGTTAGTAAATATTA						
2950	2960	2970	2980	2990	3000	3010
ACTGAGCTATGTCATATAGAGCTTCTCAGTTTGTTGTTACATACATTCTACTAAAGATTGCAAAATGGAA						
3020	3030	3040	3050	3060	3070	3080
AATGCTATTAAATTGGTTGGTGAACCACAAGATAAAATCAGTCCCACGTTGGCTCAGTTCAACTAGATGTT						
3090	3100	3110	3120	3130	3140	3150
CCCTGATACAAAGAGAACTTGTATTCTTAAACTGAAAAGCCAAACACAGCTAGCTGTCATACAAGAAAA						
3160	3170	3180	3190	3200	3210	3220
CAGCTATTATGAGACATGAAGGAGGGTAAGAATTAGCTTAAAGTTTTGCTTTGTTTTTTTTTTTTTTTT						
3230	3240	3250	3260	3270	3280	3290
ACTCAACCTATTAAATCATCTTCAACAAGAACCCACCTGATGTCACCAAGCTATTATGTTGCTGGAA						
3300	3310	3320	3330	3340	3350	3360
AAACTGGCAAGATTTCAGCTTATGTTGGCTAGCAAACACTAAGAATTGCTCTTCTTGGCCAGCCTCATAGCA						
3370	3380	3390	3400	3410	3420	3430
TAAAAGATGTGAACCTAGGAAAGTCTTCTGAGTAGCAATAAGTGGGAATTATGGGCAGAGCACACTCAA						
3440	3450	3460	3470	3480	3490	3500
TCCCCCTGTTGATTAATAAAACAGGCTGGACACTAATTAACTATGGGACTTAAATCTGTTAGAAATGAAGGA						
3510	3520	3530	3540	3550	3560	3570
GTCCAATAGCTTCTCCAATTAAACTCTAGTACATCCCTTCCCTCAAATATATATTCTAAGATAA						
3580	3590	3600	3610	3620	3630	3640
AGAGAAAGAACAGAGCACTAAGTAGAATCTGTTTTCTATTGTTAGGGCTGCTGACTCCTAGTCCT						
3650	3660	3670	3680	3690	3700	3710
TGAAGCCTAGACACATGACCCAGGAAATTTCCTTGTTCACTTTGATTATGATGTCAGGCCAAAAA						

**THIS PAGE BLANK (USPTO)**